




 Volume 44 (11) 1070-1193 November 2011
Institutional Sponsors
The Brazilian Journal of Medical and Biological Research is partially financed by 
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License 




Explore High - Performance MS
Orbitrap Technology
In Proteomics & Metabolomics
analiticaweb.com.br S C I E N T I F I C
Braz J Med Biol Res, November  2011, Volume 44(11) 1171-1176
 
doi: 10.1590/S0100-879X2011007500135
Identification of sarcopenic obesity in postmenopausal women: a 
cutoff proposal
R.J. Oliveira, M. Bottaro, J.T. Júnior, P.T.V. Farinatti, L.A. Bezerra and R.M. Lima
www.bjournal.com.br Braz J Med Biol Res 44(11) 2011
Brazilian Journal of Medical and Biological Research (2011) 44: 1171-1176
ISSN 0100-879X
Identification of sarcopenic obesity in 
postmenopausal women: a cutoff proposal
R.J. Oliveira1, M. Bottaro1, J.T. Júnior2, P.T.V. Farinatti3, 
L.A. Bezerra2 and R.M. Lima1
1Faculdade de Educação Física, Universidade de Brasília, Brasília, DF, Brasil
2Programa de Pós-Graduação em Educação Física, Universidade Católica de Brasília, Brasília, DF, Brasil
3Laboratório de Atividade Física e Promoção da Saúde, Universidade do Estado do Rio de Janeiro, 
Rio de Janeiro, RJ, Brasil
Abstract
Sarcopenic obesity is the combination of reduced fat-free mass (FFM) and increased fat mass (FM) with advancing age but 
there is lack of clear criteria for its identification. The purposes of the present investigation were: 1) to determine the prevalence 
of postmenopausal women with reduced FFM relative to their FM and height, and 2) to examine whether there are associations 
between the proposed classification and health-related variables. A total of 607 women were included in this cross-sectional 
study and were separated into two subsets: 258 older women with a mean age of 66.8 ± 5.6 years and 349 young women 
aged 18-40 years (mean age, 29.0 ± 7.5 years). All volunteers underwent body composition assessment by dual-energy X-ray 
absorptiometry. The FFM index relative to FM and height was calculated and the cutoff value corresponded to two standard 
deviations below the mean of the young reference group. To examine the clinical significance of the classification, all older 
participants underwent measurements of quadriceps strength and cardiorespiratory fitness. Values were compared between 
those who were classified as low FFM or not, using an independent samples t-test and correlations were examined. The cutoff 
corresponded to a residual of -3.4 and generated a sarcopenic obesity prevalence of 19.8% that was associated with reduced 
muscle strength and aerobic fitness among the older participants. Also, the index correlated significantly with the health-related 
fitness variables. The results demonstrated reduced functional capacity for those below the proposed cutoff and suggested 
applicability of the approach as a definition for sarcopenic obesity.
Key words: Fat-free mass; Sarcopenia; Aging; Muscle strength 
Introduction
Correspondence: R.M. Lima, Faculdade de Educação Física, UnB, Campus Universitário Darcy Ribeiro, 70910-900 Brasília, DF, 
Brasil. Fax: +55-61-3107-2500. E-mail: ricardomoreno@unb.br 
Received November 15, 2010. Accepted September 29, 2011. Available online October 14, 2011. Published November 14, 2011.
Aging is a continuous process characterized by a de-
cline in most physiological functions. Alterations that are 
widely recognized by gerontologists include the decline in 
both fat-free mass (FFM) and muscle strength, a process 
that has been referred to as sarcopenia (1). The term 
sarcopenia comes from the Greek words sarx (flesh) and 
penia (deficiency) and was originally proposed to refer 
to the involuntary loss of muscle mass that commonly 
occurs with advancing age (1-4). This phenomenon has 
been described in both elderly men and women (2) and 
has been linked to multiple negative clinical outcomes (2-
4). Sarcopenia imposes an important economic onus on 
health care costs (5), and thus efforts to understand and 
counteract this condition are meaningful. Of note, it has 
been argued that since women have less muscle mass 
compared to men, they may be at higher risk for functional 
limitations and disability (4).
Although the decline in muscle strength and mass is well 
known to have a negative effect on function and autonomy 
among older individuals, lack of clear criteria for classifica-
tion of sarcopenia leads to limitations in clinical practice 
and when performing epidemiological studies (4,6). Dual-
energy X-ray absorptiometry (DXA) has become a practi-
cal technique for measuring total body FFM and fat mass 
(FM) in clinical and research settings (2-4,6). Moreover, 
DXA permits measurements of FFM and FM for the trunk, 
arms, and legs. The sum of arm and leg FFM has been 
named appendicular FFM (AFFM), and this measure has 
been demonstrated to consistently correlate with muscle 
mass in humans across the age span (7,8). DXA is a useful 
method for distinguishing fat, bone mineral and lean tissues 
(2,6,9) and thus has an important potential for assessment 
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of age-associated changes in body composition. 
Height is a variable that is positively correlated with total 
FFM (2). In this respect, relative FFM has been frequently 
defined as AFFM divided by height squared, analogous 
to the use of body mass index (2,10). In the New Mexico 
Aging Process Study (2), cutoff values for sarcopenia were 
defined as relative AFFM two standard deviations below 
reference data of young adults aged 18-40 years, similar 
to the method used to define osteoporosis. This approach 
showed that deficiency in muscle mass increases with 
age and the prevalence of sarcopenia is associated with 
a significantly higher risk of disability in elderly individuals. 
However, in addition to the decline in FFM, older individu-
als also tend to gain weight, especially fat mass, as they 
age (3). Therefore, an expanding literature in this area has 
been focusing on a high FM/low FFM combination (4), a 
condition referred to as sarcopenic obesity (11-13). The 
combination of low muscle strength and obesity, a state 
named dynapenic-obesity, has been associated with poorer 
physical function than obesity alone (11), and thus has been 
recently examined as an important cause of frailty among 
older adults (12,13). In contrast, data reported by Bouchard 
et al. (14) have suggested that obesity per se contributes 
more to a lower physical capacity than sarcopenia, indicating 
that additional studies are warranted to better understand 
this phenomenon. 
Newman et al. (4) highlighted the importance of consid-
ering body FM when examining sarcopenia. They showed 
that, without contemplating FM, obese individuals may not 
appear to be sarcopenic even though their muscle mass 
may be reduced for their body size. These investigators (4) 
proposed an approach to determine low FFM accounting 
for FM that was shown to be related to functional limitations 
and to markers of inflammation (15) in older individuals. 
However, the importance of determining its associa-
tion with other health-related outcomes such as muscle 
strength and function has been highlighted. In addition, 
Newman et al. (4) did not establish a cutoff value below 
which individuals were classified as low FFM for their body 
size. Therefore, the purposes of the present investigation 
were: 1) to calculate the prevalence of postmenopausal 
women with reduced FFM relative to their FM and height 
(i.e., sarcopenic obesity), and 2) to examine whether there 




A total of 607 women from a program developed at 
Universidade Católica de Brasília were included in this 
cross-sectional study. The sample consisted of the two 
following subsets: 1) older women with a mean age of 66.8 
years (N = 258) who were all postmenopausal, did not have 
metallic prosthesis implants or artificial pacemakers, were 
not smokers, did not undergo hip replacement surgery, could 
walk without assistance, and did not have any metabolic 
or endocrine disorder known to affect the musculoskeletal 
system, and 2) a dataset of 349 young women aged 18-40 
years (mean age 29.0 years) with the same exclusion criteria 
who were used as reference values to define cutoff values 
for low FFM. All volunteers answered face-to-face question-
naires addressing medical history, hormone replacement 
therapy, lifestyle habits, and medication use.
After a brief verbal communication covering the objec-
tives, procedures involved, and possible risks and benefits 
of the study protocol, written informed consent was obtained 
from each participant. The study design and procedures 
were approved by the Universidade Católica de Brasíia 
Ethics Committee (protocol #024/2007). 
Anthropometry and body composition
Body weight was measured in the fasting state to the 
nearest 0.1 kg using a calibrated electronic scale with 
volunteers dressed in light T-shirt and shorts. Height was 
determined without shoes to the nearest 0.1 cm using a 
wall stadiometer, after a voluntary deep inspiration. Body 
mass index (BMI) was calculated as body weight divided 
by height squared (kg/m2).
Body composition measurements were obtained at the 
Image Laboratory of the Universidade Católica de Brasília 
using DXA (DPX-L, Lunar Radiation Corporation, USA). 
All measurements were carried out by the same trained 
technician according to procedures described elsewhere 
(3). AFFM was calculated as the sum of FFM for both 
arms and legs. In addition, AFFM was considered to be 
relative to body height squared (kg/m2). The coefficients 
of variation observed for DXA were 2.1 and 1.9% for FM 
and FFM, respectively.
Definition of sarcopenic obesity 
To account for the potential influence of FM on FFM, a 
measure of relative FFM was calculated according to the 
specifications of Newman et al. (4). Briefly, this measure is 
calculated by using a linear regression that predicts each 
volunteer’s AFFM from height (in meters) and whole-body 
fat mass (in kg). The difference between the regression-
generated prediction and the actual measured AFFM (i.e., 
residual) represents the objective value. After measuring 
relative FFM, the cutoff value for the present study was cal-
culated. Women with values equal to or below two standard 
deviations of the mean of the reference sample consisting 
of young women were classified as having reduced FFM 
for their body size. The linear regression generated the 
following equation: AFFM = -14,529 + (17,989 x height in 
meters) + (0.1307 x total fat mass in kg).
Subsequently, analyses of the young women’s values 
revealed that two standard deviations below the mean was 
a residual of -3.4. Therefore, older women who presented a 
residual equal to or below this value were considered to have 
Sarcopenic obesity in older women 1173
www.bjournal.com.br Braz J Med Biol Res 44(11) 2011
low FFM for their body size (i.e., sarcopenic obesity).
Health-related phenotype measurements
To examine the clinical significance of the proposed 
cutoff value, all older participants underwent quadriceps 
muscle strength assessment and a symptom-limited car-
diopulmonary exercise test. Both laboratory tests were 
conducted according to the procedures described below.
Isokinetic muscle strength. Dominant knee extensor 
isokinetic peak torque was evaluated using the Biodex 
System 3 dynamometer (Biodex Medical System, USA) 
(16) as previously described (3). Briefly, the testing protocol 
consisted of three sets of four knee extensor contractions 
at 60°/s with a 30-s rest between sets (17). The recorded 
value was the single muscle contraction that elicited the 
highest peak torque (PT) throughout the protocol, which 
is expressed in absolute values (Nm) as well as relative 
to body weight and FFM (Nm/kg). The equipment was 
calibrated according to manufacturer specifications before 
every testing session (18).
Cardiopulmonary exercise test. A total of 176 older 
volunteers underwent a graded cardiopulmonary exercise 
test on a treadmill (model RT 300, Moviment, Brazil) until 
voluntary exhaustion. Before testing, volunteers were pre-
pared with a three-lead electrocardiogram and were given 
basic instructions related to the procedures and use of the 
Borg scale for the rating of perceived exertion. Subjects were 
encouraged to exercise until they felt unable to continue. 
The rate of exercise intensity increments was based on a 
ramp protocol, which was designed for exhaustion achieve-
ment between 8 and 12 min. The protocol consisted of an 
initial speed and grade of 2 km/h and 0%, respectively, 
programmed to reach 6 km/h and 6% in 10 min. Blood pres-
sure was measured every 3 min with a mercury sphygmo-
manometer. Throughout the test, expired gases were 
continuously measured on a “breath-by-breath” basis 
(Cortex Metalyzer 3B, Cortex Biophysik, Germany). 
Volume and gas calibration were performed before 
each test. All tests were conducted under physician 
supervision and volunteers were allowed to hold on to 
the front treadmill handrail. Peak VO2 was calculated 
as the mean VO2 during the last minute of the test. 
Besides peak VO2, ventilatory threshold (VT) was also 
determined. The VT was the point at which there was 
a loss of linearity between oxygen uptake and carbon 
dioxide production or the point where the ventilatory 
equivalent for oxygen or end-tidal oxygen partial pres-
sure curves reached their respective minimum values 
and began to rise during the progressive exercise test 
(19,20). VT was determined by two proficient exercise 
physiologists.
Statistical analyses
Baseline data are reported as means ± SD. In-
dependent samples t-tests were used to compare 
variables between young and older women. Using the 
cutoff value proposed in this study (i.e., a residual equal 
to or below -3.4), the older women were classified as low 
FFM or not, and health-related variables were compared 
among them using an independent samples t-test. Also, 
the relationship between the residuals generated by the 
equation with muscle strength and aerobic fitness indexes 
was examined using the Pearson correlation coefficient. 
Data were considered to be significant at P < 0.05 and 
statistical analyses were performed using the SPSS 15.0 
software (SPSS, USA). 
Results
The physical characteristics of the whole sample and 
of the subgroups consisting of young or older women 
are displayed in Table 1. The older volunteers presented 
significantly lower height and greater BMI and percent 
body fat values compared to the young reference group. 
Absolute and relative FFM were significantly lower in the 
older subjects; however, total FFM did not reach statistical 
significance when comparing young vs older women.
Using the proposed cutoff value (i.e., a residual of -3.4), 
the older women were classified as having low FFM or 
not, and health-related phenotypes were compared (Table 
2). Volunteers classified as having sarcopenic obesity 
presented lower values of muscle strength, represented 
by both absolute and relative PT (P = 0.019 and < 0.001, 
respectively). Mean aerobic capacity indexes were greater 
for subjects who were not below the cutoff value, although 
statistical significance was observed only for absolute 
VO2 at VT (P = 0.047), time to VT (P = 0.033), and peak 
oxygen consumption (P = 0.015). In addition, women 
classified as low FFM had higher height (P < 0.001) and 
Table 1. Physical characteristics of the subjects as a whole and of the 
subgroups composed of young or older women.
 Total sample Young women Older women
N 607 349 258
Age (years) 44.8 ± 19.9 29.0 ± 7.5 66.8 ± 5.6
Weight (kg) 62.3 ± 12.1 59.8 ± 11.9 65.7 ± 11.7*
Height (m) 1.57 ± 0.07 1.60 ± 0.06 1.53 ± 0.07*
BMI (kg/m2) 25.4 ± 5.0 23.5 ± 4.5 28.0 ± 4.5*
Body fat (%) 35.6 ± 8.1 32.7 ± 8.2 39.6 ± 6.0*
Total FFM (kg) 38.0 ± 4.8 38.2 ± 4.5 37.7 ± 5.2
AFFM (kg) 15.8 ± 2.6 16.8 ± 2.5 14.5 ± 2.2*
Relative AFFM (kg/m2) 6.4 ± 0.8 6.6 ± 0.8 6.2 ± 0.8*
BMI = body mass index; FFM = fat-free mass; AFFM = appendicular 
fat-free mass (corresponds to the sum of arms and legs fat-free mass); 
relative AFFM corresponds to appendicular fat-free mass divided by 
height squared. *P < 0.05 compared to young women (independent 
samples t-test). 
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percent body fat (P < 0.001) values. Overall, health-related 
fitness variables were unfavorable for those classified with 
sarcopenic obesity. Reinforcing these observations, the 
residuals of the equation were significantly correlated with 
absolute (r = 0.46; P < 0.001) and relative (r = 0.41; P < 
0.001) PT, and with oxygen uptake both at VT (r = 0.22; P 
= 0.005) and at peak effort (r = 0.29; P < 0.001). 
Discussion
The main contribution of the present study is the pro-
posal of a sarcopenic obesity cutoff value below which 
postmenopausal women would be classified as having low 
FFM for their height and fat mass. To examine the possible 
clinical significance of such classification, health-related 
fitness variables were measured in the elderly sample 
and values were compared between low relative FFM and 
normal relative FFM subgroups. The results clearly pointed 
to an unfavorable profile for those below the proposed 
cutoff, specifically exhibiting lower muscle strength and 
aerobic capacity values. To our knowledge, no previous 
studies have developed a cutoff value for classifying older 
women as having low FFM for their body size and the 
present observations argue in favor of the ability to detect 
functional consequences. Obviously, future investigations 
are necessary to better examine whether this approach 
might be helpful for the screening of individuals who would 
benefit from interventions designed to increase muscle 
mass, strength, and aerobic fitness, and to decrease fat 
mass. The relevance of a cutoff value becomes important 
when considering the fact that DXA is commonly used in 
older women but the results are generally limited to the 
interpretation of bone mineral density. Nevertheless, it is 
also relevant for future studies to develop methods for sar-
copenic obesity identification based on low costs and easily 
available tools such as tapes, weight scale, stadiometer, or 
skinfold caliper, in case of inaccessibility to DXA. 
An increasing number of studies have been conducted 
to better understand the pathophysiology of sarcopenia 
(2,3,6,21), but recent literature has also focused on the obe-
sity/low muscle mass combination (22-27) with sarcopenic 
obesity described as an important public health problem 
(24,26). Initial studies proposed the clinical detection of 
sarcopenic obesity by bioelectrical impedance analysis 
(27) but later reports emphasized the importance of using 
more sophisticated measurements such as DXA through 
clinical examination (22). Although Newman et al. (4) had 
considered FM and height in their approach, they did not 
use the term sarcopenic obesity in their report. However, 
we argue that their method can be used when studying the 
obesity/low muscle mass combination. In the present study, 
we explored the Newman et al. (4) approach to define a 
cutoff value, which was a residual equal to or below -3.4, 
corresponding to at least two standard deviations below 
the mean presented by 349 young healthy women aged 
18-40 years, analogous to the study of Baumgartner et al. 
(2). The observed cutoff value appeared to be plausible 
since individuals classified as low FFM also exhibited 
significantly lower values of muscle strength and aerobic 
fitness indexes. Moreover, the prevalence observed among 
Table 2. Health-related physical fitness variables according to classification of sar-
copenic obesity using the cutoff value proposed in the present study.
Sarcopenic obesity Non-sarcopenic obesity
N (%) 49 (19.8%) 198 (80.2%)
Age (years) 67.0 ± 5.7 66.5 ± 5.5
Weight (kg) 68.7 ± 11.4 65.1 ± 11.5
Height (m) 1.57 ± 0.05 1.52 ± 0.06*
BMI (kg/m2) 28.0 ± 4.4 28.0 ± 4.5
Percent body fat (%) 43.3 ± 4.3 38.6 ± 6.0*
PT (Nm) 87.5 ± 17.8 96.0 ± 23.4*
PT relative to body weight (Nm/kg) 1.3 ± 0.2 1.5 ± 0.3*
Relative VO2 at VT (mL·kg-1·min-1) 12.1 ± 2.3 12.7 ± 2.5
Absolute VO2 at VT (L/min) 0.8 ± 0.2 0.8 ± 0.2*
Time at VT (s) 261.6 ± 89.4 299.4 ± 97.1*
Peak relative VO2 (mL·kg-1·min-1) 16.5 ± 2.8 17.3 ± 3.3
Peak absolute VO2 (L/min) 1.0 ± 0.2 1.1 ± 0.3*
Time to exhaustion (s) 566.2 ± 124.0 590.7 ± 125.5
BMI = body mass index; PT = peak torque; VO2 = oxygen consumption; VT = ventila-
tory threshold. The cutoff value was two standard deviations below the mean of the 
young reference group and corresponded to a residual of -3.4. *P < 0.05 compared 
to sarcopenic obesity (independent samples t-test).
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older women was 19.8%, in agreement with previous 
studies (2,4,25). 
Practical applications of the present investigation are 
easily envisioned. When performing DXA in older post-
menopausal women similar to those studied here, values 
of height in meters and FM in kilograms should be applied 
in the following equation: AFFM = -14,529 + (17,989 x 
height in meters) + (0.1307 x total fat mass in kg). The result 
corresponds to the expected AFFM based on height and 
FM, and thus should be subtracted from the actual AFFM 
(i.e., the sum of arm and leg FFM measured by DXA). If 
the residual is equal to or below -3.4 the individual is clas-
sified as having sarcopenic obesity and is likely to exhibit 
low values of muscle strength and aerobic fitness. These 
calculations can be easily performed using software follow-
ing the DXA exams and can provide assessment of FFM 
and FM in addition to bone mineral density calculations. 
The procedure would permit classifying a postmenopausal 
woman as having reduced FFM for her body size, leading 
clinically relevant follow-up. 
The present study is not without limitations. The sample 
was composed of older Brazilian women and thus the results 
cannot be extrapolated to other populations or be applied 
to men. Moreover, the cross-sectional design of the study 
does not establish cause-effect relationships between sar-
copenic obesity and the examined health-related variables. 
Finally, after this initial investigation, future studies should 
reproduce the observations, investigate further the potential 
use of the classification proposed here in clinical settings 
and examine its association with other clinical outcomes 
such as cardiovascular and metabolic risk factors.
The present study proposes an approach for identify-
ing postmenopausal women with reduced FFM for their 
body size. The observed prevalence was approximately 
20% and was associated with reduced muscle strength 
and aerobic fitness indexes. The condition of low muscle 
mass/high fat mass has been named sarcopenic obesity 
and thus the cutoff value presented here can be an option 
for its identification. 
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